Váš Lekár - polyclinic and pharmacies
In the second investment round, investors have the opportunity to co-own a share in the Váš Lekár holding, which includes:
- Modern Polyclinic in prestigious Eurovea - a part of Bratislava Central Business District.
- Network of 7 pharmacies and 6 medical offices across Slovakia.
- Lab28 event venue and coworking space in premium office building Nivy Tower, Bratislava.
The Váš Lekár Polyclinic commenced full-scale operations in 2024, featuring 24 medical offices and an expanding patient base, including corporate clients. The polyclinic has successfully secured contracts with all major health insurance providers and key strategic partners. Meanwhile, the existing network of regional pharmacies, integrated with diagnostic centers, and medical offices, has validated the business model with positive performance.
Currently, in a dynamic growth phase, the group anticipates revenue expansion from €0.4 million to over €4.5 million within its first partial year of operation.
The strategic objective is to accelerate expansion and solidify the Váš Lekár brand in the regional pharmacy sector, particularly by integrating diagnostic centers, where the acquisition strategy has been set. Additionally, preparations are underway for the potential entry of a major investor. Capital will be strategically deployed to acquire profitable pharmacies, enhance the headquarters and polyclinic operations in Eurovea, Bratislava, and scale the business.
By 2028, the plan is to establish a network of up to 50 pharmacies, including in underserved areas, through the acquisition of successful regional businesses and the launch of new Váš Lekár premises.
Investment Opportunity
Become a co-owner of a well-established healthcare business, strategically located in a prime area of the new modern city center. This investment offers equity participation in a diversified portfolio of healthcare enterprises under the reputable Váš Lekár brand.
Investment Highlights:
- Equity investment in the holding company, with a pre-money valuation of €8.25 million.
- Equity stake of up to 25% available for investors.
- Expected return on capital: 2.5x to 4.0x the initial investment or a targeted annual return exceeding 20%+.
Sources of Returns:
- Exit opportunities via the sale of individual companies, the entire holding, or investor shares upon the entry of a new strategic partner.
- Dividend distributions following the group's transition to profitability.
This is a rare opportunity to invest in a high-growth healthcare sector with strong potential for long-term value creation.
Why invest?
About the company
Portfolio and results
Risks
*Investing carries the risk of partial or complete loss of capital. The investment opportunity in the target company is facilitated by Crowdberry Investment Platform j.s.a.